Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for Premature Infants With Bronchopulmonary Dysplasia
NCT07120971Phase 1Recruiting
- Sponsor
- Medical College of Wisconsin
- Start
- Dec 2025
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of metformin in bronchopulmonary dysplasia (BPD) (9 cohorts), sponsored by Medical College of Wisconsin. Primary endpoints: Number of participants who tolerate metformin at 14 days, Number of participants with treatment-related adverse events at 14 days and 7 more. Started Dec 2025; status: recruiting.
02
Drugs
metformin
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on NCT07120971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07120971.